Humacyte, Inc. (HUMA) bonds
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.60+0.00 (+0.63%)
Close on Nov 12, 2026Market cap $165.40MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Humacyte reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2022
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Humacyte's 10-Q for the period ended Jun 30, 2026
| Issue | Carrying value |
|---|---|
| Revenue Interest Purchase Agreement | $0 |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn | Expires |
|---|---|---|---|---|
| Term Loan Facility due 2029 | $77.50M | $25.00M | $40.30M | Dec 1, 2029 |
| Loan Agreement Conversion Derivative Liability | $77.50M | – | – | – |
See a number that looks wrong?